Advertisement

Multiple Facets of Estrogen Receptor in Human Breast Cancer

  • Leigh C. Murphy
  • Etienne Leygue
  • Helmut Dotzlaw
  • Amanda Coutts
  • Biao Lu
  • Aihua Huang
  • Peter H. Watson
Part of the Contemporary Endocrinology book series (COE)

Abstract

Estrogen is a major regulator of mammary gland development and function, and affects the growth and progression of mammary cancers (1,2). In particular, the growth responsiveness of breast cancer (BC) cells to estrogen is the basic rationale for the efficacy of the so-called endocrine therapies, such as antiestrogens. Estrogens mediate their action via the estrogen receptor (ER), which belongs to the steroid/thyroid/retinoid receptor gene superfamily (3). The protein products of this family are intracellular, ligand-activated transcription factors regulating the expression of several gene products, which ultimately elicit a target tissue-specific response (4). Indeed, ER, together with progesterone receptor (PR), expression in human breast tumors, are important prognostic indicators, as well as markers of responsiveness to endocrine therapies (5, 6). However, although the majority of human BCs are thought to be initially hormone-responsive, it is well appreciated that alterations in responsiveness to estrogen occurs during breast tumorigenesis. During BC progression, some ER-positive BCs are de novo resistant to endocrine therapies, and of those that originally respond to antiestrogens, many develop resistance. This progression from hormonal dependence to independence is a significant clinical problem, because it limits the useful of the relatively nontoxic endocrine therapies, and is associated with a more aggressive disease phenotype (7). This occurs despite the continued expression of ER, and often PR (8,9). The ER is pivotal in estrogen and antiestrogen action in any target cell, but the nature of the ER is clearly multifaceted.

Keywords

Estrogen Receptor Human Breast Tumor Human Breast Tissue Breast Tumorigenesis Human Estrogen Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Vorherr H. Breast Cancer. Urban & Schwarzenberg, Baltimore, 1980.Google Scholar
  2. 2.
    Clarke R, Skaar T, Baumann K, Leonessa F, James M, Lippman M, et al. Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression. Breast Cancer Res Treat 1994; 31: 237–248.PubMedCrossRefGoogle Scholar
  3. 3.
    Green S, Kumar V, Krust A, Walter P, Chambon P. Structural and functional domains of the estrogen receptor. Cold Spring Harbor Symp Quant Biol 1986; 51: 751–758.PubMedCrossRefGoogle Scholar
  4. 4.
    Tsai MJ, O’Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily. Annu Rev Biochem 1994; 63: 451–486.PubMedCrossRefGoogle Scholar
  5. 5.
    Horwitz KB, McGuire WL, Pearson OH, Segaloff A. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 1975; 189: 726, 727.Google Scholar
  6. 6.
    Horwitz K, Koseki Y, McGuire W. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 1978; 103: 1742–1751.PubMedCrossRefGoogle Scholar
  7. 7.
    Murphy L. Mechanisms associated with the progression of breast cancer from hormone dependence to independence. Pezcoller Foundation J 1995; 2: 6–16.Google Scholar
  8. 8.
    Taylor R, Powles T, Humphreys J, Bettelheim R, Dowsett M, Casey A, Neville A, Coombes R. Effects of endocrine therapy on steroid-receptor content of breast cancer. Br J Cancer 1982; 45: 80–84.PubMedCrossRefGoogle Scholar
  9. 9.
    Katzenellenbogen B. Antiestrogen resistance: mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy. J Natl Cancer Inst 1991; 83: 1434, 1435.Google Scholar
  10. 10.
    Mosselman S, Polman J, Dijkema R. ER-beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392: 49–53.PubMedCrossRefGoogle Scholar
  11. 11.
    Kuiper G, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93: 5925–5930.PubMedCrossRefGoogle Scholar
  12. 12.
    Dotzlaw H, Leygue E, Watson P, Murphy L. Expression of estrogen receptor-beta in human breast tumors. J Clin Endocrinol Metab 1997; 82: 2371–2374.PubMedCrossRefGoogle Scholar
  13. 13.
    Lu B, Leygue E, Dotzlaw H, Murphy LJ, Murphy LC, Watson PH. Estrogen receptor-beta mRNA variants in human and murine tissues. Mol Cell Endocrinol 1998; 138: 199–203.PubMedCrossRefGoogle Scholar
  14. 14.
    Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjold M, Gustafsson J-A. Human estrogen receptor 13 gene structure, chromosomal localization and expression pattern. J Clin Endocrinol Metab 1997; 82: 4258–4265.PubMedCrossRefGoogle Scholar
  15. 15.
    Murphy L, Leygue E, Dotzlaw H, Douglas D, Coutts A, Watson P. Oestrogen receptor variants and mutations in human breast cancer. Ann Med 1997; 29: 221–234.PubMedCrossRefGoogle Scholar
  16. 16.
    Murphy L, Dotzlaw H, Leygue E, Coutts A, Watson P. The Pathophysiological role of estrogen receptor variants in human breast cancer. J Steroid Biochem Mol Biol 1998; 65: 175–180.PubMedCrossRefGoogle Scholar
  17. 17.
    Moore J, McKee D, Slentz-Kesler K, Moore L, Jones S, Horne E, et al. Cloning and characterization of human estrogen receptor 13 isoforms. Biochem Biophys Res Commun 1998; 247: 75–78.PubMedCrossRefGoogle Scholar
  18. 18.
    Vladusic E, Hornby A, Guerra-Vladusic F, Lupu R. Expression of estrogen receptor 13 messenger RNA variant in breast cancer. Cancer Res 1998; 58: 210–214.PubMedGoogle Scholar
  19. 19.
    Murphy L, Dotzlaw H, Leygue E, Douglas D, Coutts A, Watson P. Estrogen receptor variants and mutations: a review. J Steroid Biochem Mol Biol 1997; 62: 363–372.PubMedCrossRefGoogle Scholar
  20. 20.
    McGuire WL, Chamness GC, Fuqua SA. Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 1991; 5: 1571–1577.PubMedCrossRefGoogle Scholar
  21. 21.
    Dotzlaw H, Alkhalaf M, Murphy LC. Characterization of estrogen receptor variant mRNAs from human breast cancers. Mol Endocrinol 1992; 6: 773–785.PubMedCrossRefGoogle Scholar
  22. 22.
    Fuqua SA, Allred DC, Auchus RJ. Expression of estrogen receptor variants. J Cell Biochem 1993; 17G(S uppl): 194–197 .Google Scholar
  23. 23.
    Murphy LC, Dotzlaw H. Variant estrogen receptor mRNA species detected in human breast cancer biopsy samples. Mol Endocrinol 1989; 3: 687–693.PubMedCrossRefGoogle Scholar
  24. 24.
    Leygue E, Huang A, Murphy L, Watson P. Prevalence of estrogen receptor variant messenger RNAs in human breast cancer. Cancer Res 1996; 56: 4324–4327.PubMedGoogle Scholar
  25. 25.
    Murphy LC, Hilsenbeck SG, Dotzlaw H, Fuqua SAW. Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer. Clin Cancer Res 1995; 1: 155–159.PubMedGoogle Scholar
  26. 26.
    Leygue E, Murphy L, Kuttenn F, Watson P. Triple primer polymerase chain reaction. A new way to quantify truncated mRNA expression. Am J Pathol 1996; 148: 1097–1103.PubMedGoogle Scholar
  27. 27.
    Leygue ER, Watson PH, Murphy LC. Estrogen receptor variants in normal human mammary tissue. J Natl Cancer Inst 1996; 88: 284–290.PubMedCrossRefGoogle Scholar
  28. 28.
    Pfeffer U, Fecarotta E, Vidali G. Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and in MCF-7 cells. Cancer Res 1995; 55: 2158–2165.PubMedGoogle Scholar
  29. 29.
    Erenburg I, Schachter B, Lopez RM, Ossowski L. Loss of an estrogen receptor isoform (ER-alpha deleted 3) in breast cancer and the consequences of its reexpression: interference with estrogen-stimulated properties of malignant transformation. Mol Endocrinol 1997; 11: 2004–2015.PubMedCrossRefGoogle Scholar
  30. 29a.
    Leygue E, Dotzlaw H, Watson PH, Murphy LC. Altered expression of estrogen receptor-a variant messenger RNAs between adjacent normal breast and breast tumor tissues. Breast Cancer Res 1999; 51: 2–10.Google Scholar
  31. 30.
    Wang Y, Miksicek RJ. Identification of a dominant negative form of the human estrogen receptor. Mol Endocrinol 1991; 5: 1707–1715.PubMedCrossRefGoogle Scholar
  32. 31.
    Leygue E, Dotzlaw H, Watson PH, Murphy LC. Identification of novel exon-deleted progesterone receptor variant mRNAs in human breast tissue. Biochem Biophys Res Commun 1996; 228: 63–68.PubMedCrossRefGoogle Scholar
  33. 32.
    Richter J, Lange C, Wierman A, Brooks K, Tung L, Takimoto G, Horwitz KB. Progesterone receptor variants found in breast cells repress transcription by wild type receptors. Breast Cancer Res Treat 1998; 48: 231–241.CrossRefGoogle Scholar
  34. 33.
    Gallacchi P, Schoumacher F, Eppenberger-Castori S, Landenberg EV, Kueng W, Eppenberger U, Mueller H. Increased expression of estrogen receptor exon 5 deletion variant in relapse tissues of human breast cancer. Int J Cancer 1998; 79: 44–48.PubMedCrossRefGoogle Scholar
  35. 34.
    Leygue E, Hall R, Dotzlaw H, Watson P, Murphy L. Estrogen receptor-alpha variant mRNA expression in primary human breast tumors and matched lymph node metastases. Br J Cancer 1999; 79: 978–983.PubMedCrossRefGoogle Scholar
  36. 35.
    Garcia T, Lehrer S, Bloomer WD, Schachter B. A variant estrogen receptor messenger ribonucleic acid is associated with reduced levels of estrogen binding in human mammary tumors. Mol Endocrinol 1988; 2: 785–791.PubMedCrossRefGoogle Scholar
  37. 36.
    Fuqua SA, Fitzgerald SD, Chamness GC, Tandon AK, McDonnell DP, Nawaz Z, O’Malley BW, McGuire WL. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 1991; 51: 105–109.PubMedGoogle Scholar
  38. 37.
    Daffada AA, Johnston SR, Smith IE, Detre S, King N, Dowsett M. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. Cancer Res 1995; 55: 288–293.PubMedGoogle Scholar
  39. 38.
    Zhang QX, Borg A, Fuqua SA. An exon 5 deletion variant of the estrogen receptor frequently coexpressed with wild type estrogen receptor in human breast cancer. Cancer Res 1993; 53: 5882–5884.PubMedGoogle Scholar
  40. 39.
    Desai A, Luqmani Y, Coope R, Dagg B, Gomm J, Pace P, et al. Presence of exon 5 deleted oestrogen receptor in human breast cancer: functional analysis and clinical significance. Br J Cancer 1997; 75: 1173–1184.PubMedCrossRefGoogle Scholar
  41. 40.
    Chaidarun S, Alexander J. A tumor specific truncated estrogen receptor splice variant enhances estrogen stimulated gene expression. Mol Endocrinol 1998; 12: 1355–1366.PubMedCrossRefGoogle Scholar
  42. 41.
    Rea D, Parker MG. Effects of an exon 5 variant of the estrogen receptor in MCF-7 breast cancer cells. Cancer Res 1996; 56: 1556–1563.PubMedGoogle Scholar
  43. 42.
    Fuqua SA, Wolf DM. Molecular aspects of estrogen receptor variants in breast cancer. Breast Cancer Res Treat 1995; 35: 233–241.PubMedCrossRefGoogle Scholar
  44. 43.
    Coutts A, Davie J, Dotzlaw H, Murphy L. Estrogen regulation of nuclear matrix-intermediate filament proteins in human breast cancer cells. J Cell Biochem 1996; 63: 174–184.PubMedCrossRefGoogle Scholar
  45. 44.
    Coutts A, Leygue E, Murphy L. Mechanisms of hormone independence in human breast cancer cells. Abstract. 1998. In: 88th Annual Meeting of the American Association for Cancer Research pp. 296, San Diego, CA, 1997.Google Scholar
  46. 45.
    Madsen MW, Reiter BE Lykkesfeldt AE. Differential expression of estrogen receptor mRNA splice variants in the tamoxifen resistant human breast cancer cell line, MCF-7/TAMR-1 compared to the parental MCF-7 cell line. Mol Cell Endocrinol 1995; 109: 197–207.PubMedCrossRefGoogle Scholar
  47. 46.
    Madsen MW, Reiter BE, Larsen SS, Briand P, Lykkesfeldt AE. Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells. Cancer Res 1997; 57: 585–589.PubMedGoogle Scholar
  48. 47.
    Brunner N, Boysen B, Jirus S, Skaar T, Holst-Hanson C, Lippman J, et al. MCF7/LCC9: an antiestrogen resistant MCF 7 variant in which acquired resistance to the steroidal antiestrogen ICI 182780 confers an early cross resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res 1997; 57: 3486–3493.PubMedGoogle Scholar
  49. 48.
    Karnik PS, Kulkarni S, Liu XP, Budd GT, Bukowski RM. Estrogen receptor mutations in tamoxifenresistant breast cancer. Cancer Res 1994; 54: 349–353.PubMedGoogle Scholar
  50. 49.
    Huang A, Pettigrew N, Watson P. Immunohistochemical assay for oestrogen receptors in paraffin wax sections of breast carcinoma using a new monoclonal antibody. J Pathol 1996; 180: 223–227.PubMedCrossRefGoogle Scholar
  51. 50.
    Huang A, Leygue E, Snell L, Murphy L, Watson P. Expression of estrogen receptor variants mRNAs and determination of estrogen status in human breast cancer. Am J Pathol 1997; 150: 1827–1833.PubMedGoogle Scholar
  52. 51.
    Castles CG, Fuqua SA, Klotz DM, Hill SM. Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res 1993; 53: 5934–5939.PubMedGoogle Scholar
  53. 52.
    Park W, Choi J, Hwang E, Lee J. Identification of a variant estrogen receptor lacking exon 4 and its coexpression with wild type estrogen receptor in ovarian carcinomas. Clin Cancer Res 1996; 2: 2029–2035.PubMedGoogle Scholar
  54. 53.
    Tremblay G, Tremblay A, Copeland N, Gilbert D, Jenkins N, Labrie F, Giguere V. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor (3. Mol Endocrinol 1997; 11: 353–365.PubMedCrossRefGoogle Scholar
  55. 54.
    Paech K, Webb P, Kuiper G, Nilsson S, Gustafsson JA, Kushner PJ, Scanlan TS. Differential ligand activation of estrogen receptors ER alpha and ER beta at APl sites. Science 1997; 277: 1508–1510.PubMedCrossRefGoogle Scholar
  56. 55.
    Cowley S, Hoare S, Mosselman S, Parker M. Estrogen receptors alpha and beta form heterodimers on DNA. J Biol Chem 1997;272:19, 858–19, 862.Google Scholar
  57. 56.
    Pettersson K, Grandien K, Kuiper GG, Gustafsson JA. Mouse estrogen receptor beta forms estrogen response element-binding heterodimers with estrogen receptor alpha. Mol Endocrinol 1997; 11: 1486 1496.Google Scholar
  58. 57.
    Colditz G. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 1998; 90: 814–823.PubMedCrossRefGoogle Scholar
  59. 58.
    Leygue E, Dotzlaw H, Watson P, Murphy L. Altered estrogen receptor alpha and beta mRNA expression during human breast tumorigenesis. Cancer Res 1998; 58: 3197–3201.PubMedGoogle Scholar
  60. 59.
    Leygue E, Dotzlaw H, Hare H, Watson P, Murphy L. Expression of estrogen receptor beta variant mRNAs in human breast tumors. Breast Cancer Res Treat 1997; 46, 48 (Abstract).Google Scholar
  61. 60.
    Chu S, Fuller P. Identification of a splice variant of the rat estrogen receptor (3 gene. Mol Cell Endocrinol 1997; 132: 195–199.PubMedCrossRefGoogle Scholar
  62. 61.
    Petersen D, Tkalcevic G, Koza-Taylor P, Turi T Brown T. Identification of estrogen receptor [32, a functional variant of estrogen receptor [3 expressed in normal rat tissues. Endocrinology 1998; 139: 1082–1092.PubMedCrossRefGoogle Scholar
  63. 62.
    Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, Muramatsu M. Molecular cloning and characterization of human estrogen receptor (3cx: potential inhibitor of estrogen action in human. Nucleic Acids Res 1998; 26: 3505–3512.PubMedCrossRefGoogle Scholar
  64. 63.
    Watanabe T, Inoue S, Ogawa S, Ishii Y, Hiroi H, Ikeda K, Orimo A, Muramatsu M. Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context and estrogen receptor subtype: functional differences between estrogen receptors a and 13. Biochem Biophys Res Commun 1997; 236: 140–145.PubMedCrossRefGoogle Scholar
  65. 64.
    Leygue E, Dotzlaw H, Lu B, Glor C, Watson P, Murphy L. Estrogen receptor-beta: mine is longer than yours? J Clin Endocrinol Metab 1998; 83: 3754–3755.PubMedCrossRefGoogle Scholar
  66. 65.
    Graham J, Yeates C, Balleine R, Harvey S, Milliken J, Bilou M, Clarke C. Characterization of progesterone A and B expression in human breast cancer. Cancer Res 1995; 55: 5063–5068.PubMedGoogle Scholar
  67. 66.
    Yeates C, Hunt S, Balleine R, Clarke C. Characterization of a truncated progesterone receptor protein in breast tumors. J Clin Endocrinol Metab 1998; 83: 460–467.PubMedCrossRefGoogle Scholar
  68. 67.
    Clark GM, McGuire WL, Hubay CA, Pearson OH, Marshall JS. Progesterone receptors as a prognostic factor in stage II breast cancer. N Engl J Med 1983; 309: 1343–1347.PubMedCrossRefGoogle Scholar
  69. 68.
    Huang A, Leygue E, Dotzlaw H, Murphy L, Watson P. Estrogen receptor-ct mRNA variants influence the determination of estrogen receptor status in human breast cancer. Breast Cancer Res Treat 1999; 58: 219–225.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2000

Authors and Affiliations

  • Leigh C. Murphy
  • Etienne Leygue
  • Helmut Dotzlaw
  • Amanda Coutts
  • Biao Lu
  • Aihua Huang
  • Peter H. Watson

There are no affiliations available

Personalised recommendations